Search

Displaying all 5 results
DrugBest match

Duvelisib

go.drugbank.com/drugs/DB11952
ApprovedInvestigational

Duvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative and innate immune cell inhibitory activity. All the work around duvelisib showed ...

  1. Indication

    Relapsed Chronic Lymphocytic Leukemia

    go.drugbank.com/conditions/DBCOND0060745
    Drugs: Duvelisib · Idelalisib · Lisocabtagene maraleucel · Pirtobrutinib
  2. Indication

    Refractory Small Lymphocytic Lymphoma

    go.drugbank.com/conditions/DBCOND0029146
    Drugs: Duvelisib · Lisocabtagene maraleucel · Pirtobrutinib
  3. Indication

    Relapsed Small Lymphocytic Lymphoma

    go.drugbank.com/conditions/DBCOND0023539
    Drugs: Duvelisib · Idelalisib · Lisocabtagene maraleucel · Pirtobrutinib
  4. Indication

    Refractory Chronic Lymphocytic Leukemia (CLL)

    go.drugbank.com/conditions/DBCOND0146058
    Drugs: Duvelisib · Lenalidomide · Lisocabtagene maraleucel · Ofatumumab · Pirtobrutinib